No execution: Courts side with inmate wanting pastor present
Kim Chandler
Updated:
Tags:
FILE-This undated file photo provided by the Alabama Department of Corrections shows Willie B. Smith III. The Alabama Supreme Court on Tuesday, Dec. 1, 2020 ordered that Smith III be put to death on Feb. 11, 2021 for the shotgun slaying of Sharma Ruth Johnson. The lethal injection of Willie B. Smith III was called off Thursday, Feb. 11, 2021, when the U.S. Supreme Court maintained an injunction. The state prison system said the execution would not proceed given the ruling.(Alabama Department of Corrections via AP)
ATMORE, Ala. – An Alabama inmate won a reprieve from a planned lethal injection after the U.S. Supreme Court said the state must allow his personal pastor in the death chamber.
COSHOCTON, Ohio, Jan. 26, 2021 /PRNewswire/ Having not just one but two products receive two gold stars from the prestigious International Taste Institute is reason to celebrate. Receiving the remarkable honor for two different formulas is continuing proof of Wiley’s Finest® efforts to deliver the finest, best-tasting products for our customers. “Exceptional quality taste is something we never take for granted, but strive to be worthy of every day,” said Sam Wiley, Chief Eater of Omega-3s (CEO). Wiley’s Finest® CatchFree™ Omega Full Spectrum Omega 3 Liquid and Summit DHA™ products were both awarded 2-stars by the some of the world’s leading sensory experts at the International Taste Institute.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Amryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
Amryt Pharma plcJanuary 20, 2021 GMT
Amryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
DUBLIN, Ireland, and Boston MA, January 20, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, is pleased to announce that the National Institute for Health and Care Excellence (“NICE”) has approved Myalepta® (metreleptin) for reimbursement in England and Wales as an adjunct to diet as replacement therapy for the treatment of leptin deficiency in patients with congenital or acquired general lipodystrophy (GL) in adults and children two years of age and above and fa